JENNIFER LEWIS: Open Payments
NPI 1487421384 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,939 in 134 payments from 27 companies in 2025. Trend: 2023 $0 · 2024 $2,051 · 2025 $2,939
Food & beverage: $2,939
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 25 | $588 |
| GlaxoSmithKline, LLC. | 17 | $355 |
| Novo Nordisk Inc | 10 | $248 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $204 |
| Neurocrine BioSciences, Inc. | 3 | $172 |
| PFIZER INC. | 9 | $166 |
| Abbott Laboratories | 7 | $165 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $115 |
| Exact Sciences Corporation | 5 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
Products named: TRELEGY ELLIPTA, BREZTRI, FARXIGA, ELIQUIS, JARDIANCE, INGREZZA, FREESTYLE LIBRE 3, AIRSUPRA.
Industry payments across CT — which companies pay providers there.
